Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children

NCT05099029 is registered in ClinicalTrials.gov with Enimmune Corporation as lead sponsor.

NCT NCT05099029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05099029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
Lead sponsor
Enimmune Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 27, 2018
Completion date
July 31, 2024
Enrollment
3,982 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

enterovirus infections